vs
CATALYST PHARMACEUTICALS, INC.（CPRX）与STURM RUGER & CO INC（RGR）财务数据对比。点击上方公司名可切换其他公司
CATALYST PHARMACEUTICALS, INC.的季度营收约是STURM RUGER & CO INC的1.0倍（$152.6M vs $151.1M），CATALYST PHARMACEUTICALS, INC.同比增速更快（7.6% vs 3.6%），CATALYST PHARMACEUTICALS, INC.自由现金流更多（$44.9M vs $12.3M），过去两年CATALYST PHARMACEUTICALS, INC.的营收复合增速更高（24.5% vs 5.1%）
Catalyst Pharmaceuticals是一家总部位于美国佛罗里达州科勒尔盖布尔斯的生物制药企业，专注于罕见病药物研发。核心产品包括用于治疗兰伯特-伊顿肌无力综合征（LEMS）的氨吡啶磷酸盐，商品名为Firdapse。该药物2018年11月获FDA批准，除原有成人适应症外，还可用于6岁及以上的LEMS儿童患者。
鲁格公司（Ruger）是总部位于美国康涅狄格州绍斯波特的枪械制造企业，除总部外，还在新罕布什尔州纽波特、北卡罗来纳州梅约丹以及亚利桑那州普雷斯科特设有生产工厂。公司由亚历山大·麦考密克·斯特姆与威廉·B·鲁格于1949年共同创立，自1969年起公开上市交易。
CPRX vs RGR — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $152.6M | $151.1M |
| 净利润 | $52.7M | — |
| 毛利率 | 82.9% | 17.8% |
| 营业利润率 | 40.5% | 2.3% |
| 净利率 | 34.5% | — |
| 营收同比 | 7.6% | 3.6% |
| 净利润同比 | -5.8% | — |
| 每股收益（稀释后） | $0.40 | $0.22 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $152.6M | $151.1M | ||
| Q3 25 | $148.4M | $126.8M | ||
| Q2 25 | $146.6M | $132.5M | ||
| Q1 25 | $141.4M | $135.7M | ||
| Q4 24 | $141.8M | $145.8M | ||
| Q3 24 | $128.7M | $122.3M | ||
| Q2 24 | $122.7M | $130.8M | ||
| Q1 24 | $98.5M | $136.8M |
| Q4 25 | $52.7M | — | ||
| Q3 25 | $52.8M | $1.6M | ||
| Q2 25 | $52.1M | $-17.2M | ||
| Q1 25 | $56.7M | $7.8M | ||
| Q4 24 | $55.9M | — | ||
| Q3 24 | $43.9M | $4.7M | ||
| Q2 24 | $40.8M | $8.3M | ||
| Q1 24 | $23.3M | $7.1M |
| Q4 25 | 82.9% | 17.8% | ||
| Q3 25 | 84.7% | 15.1% | ||
| Q2 25 | 85.9% | 3.9% | ||
| Q1 25 | 87.3% | 22.0% | ||
| Q4 24 | 84.7% | 22.8% | ||
| Q3 24 | 85.0% | 18.5% | ||
| Q2 24 | 87.4% | 22.3% | ||
| Q1 24 | 87.3% | 21.5% |
| Q4 25 | 40.5% | 2.3% | ||
| Q3 25 | 44.7% | -2.7% | ||
| Q2 25 | 45.2% | -15.6% | ||
| Q1 25 | 44.8% | 6.2% | ||
| Q4 24 | 44.3% | 7.8% | ||
| Q3 24 | 39.6% | 3.1% | ||
| Q2 24 | 44.2% | 6.9% | ||
| Q1 24 | 27.5% | 5.5% |
| Q4 25 | 34.5% | — | ||
| Q3 25 | 35.6% | 1.2% | ||
| Q2 25 | 35.6% | -13.0% | ||
| Q1 25 | 40.1% | 5.7% | ||
| Q4 24 | 39.4% | — | ||
| Q3 24 | 34.1% | 3.9% | ||
| Q2 24 | 33.2% | 6.3% | ||
| Q1 24 | 23.6% | 5.2% |
| Q4 25 | $0.40 | $0.22 | ||
| Q3 25 | $0.42 | $0.10 | ||
| Q2 25 | $0.41 | $-1.05 | ||
| Q1 25 | $0.45 | $0.46 | ||
| Q4 24 | $0.44 | $0.62 | ||
| Q3 24 | $0.35 | $0.28 | ||
| Q2 24 | $0.33 | $0.47 | ||
| Q1 24 | $0.19 | $0.40 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $709.2M | $92.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $954.3M | $283.8M |
| 总资产 | $1.1B | $342.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $709.2M | $92.5M | ||
| Q3 25 | $689.9M | $80.8M | ||
| Q2 25 | $652.8M | $101.4M | ||
| Q1 25 | $580.7M | $108.3M | ||
| Q4 24 | $517.6M | $105.5M | ||
| Q3 24 | $442.3M | $96.0M | ||
| Q2 24 | $375.7M | $105.6M | ||
| Q1 24 | $310.4M | $115.3M |
| Q4 25 | $954.3M | $283.8M | ||
| Q3 25 | $920.2M | $279.6M | ||
| Q2 25 | $856.0M | $289.3M | ||
| Q1 25 | $794.3M | $321.5M | ||
| Q4 24 | $727.6M | $319.6M | ||
| Q3 24 | $660.9M | $314.9M | ||
| Q2 24 | $608.7M | $321.5M | ||
| Q1 24 | $561.4M | $332.0M |
| Q4 25 | $1.1B | $342.0M | ||
| Q3 25 | $1.1B | $342.3M | ||
| Q2 25 | $971.9M | $349.5M | ||
| Q1 25 | $908.9M | $379.0M | ||
| Q4 24 | $851.4M | $384.0M | ||
| Q3 24 | $772.0M | $373.5M | ||
| Q2 24 | $706.4M | $376.7M | ||
| Q1 24 | $646.7M | $385.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $44.9M | $15.5M |
| 自由现金流经营现金流 - 资本支出 | $44.9M | $12.3M |
| 自由现金流率自由现金流/营收 | 29.4% | 8.2% |
| 资本支出强度资本支出/营收 | 0.0% | 2.1% |
| 现金转化率经营现金流/净利润 | 0.85× | — |
| 过去12个月自由现金流最近4个季度 | — | $38.5M |
8季度趋势，按日历期对齐
| Q4 25 | $44.9M | $15.5M | ||
| Q3 25 | $32.4M | $12.9M | ||
| Q2 25 | $71.3M | $14.7M | ||
| Q1 25 | $60.0M | $11.1M | ||
| Q4 24 | $70.9M | $20.0M | ||
| Q3 24 | $72.9M | $9.4M | ||
| Q2 24 | $64.1M | $18.7M | ||
| Q1 24 | $31.9M | $7.3M |
| Q4 25 | $44.9M | $12.3M | ||
| Q3 25 | — | $7.0M | ||
| Q2 25 | $71.3M | $9.1M | ||
| Q1 25 | — | $10.0M | ||
| Q4 24 | $70.8M | $16.4M | ||
| Q3 24 | $72.6M | $2.6M | ||
| Q2 24 | $64.1M | $10.1M | ||
| Q1 24 | $31.7M | $5.6M |
| Q4 25 | 29.4% | 8.2% | ||
| Q3 25 | — | 5.5% | ||
| Q2 25 | 48.6% | 6.9% | ||
| Q1 25 | — | 7.4% | ||
| Q4 24 | 49.9% | 11.2% | ||
| Q3 24 | 56.4% | 2.1% | ||
| Q2 24 | 52.3% | 7.7% | ||
| Q1 24 | 32.2% | 4.1% |
| Q4 25 | 0.0% | 2.1% | ||
| Q3 25 | 0.0% | 4.6% | ||
| Q2 25 | 0.0% | 4.2% | ||
| Q1 25 | 0.0% | 0.8% | ||
| Q4 24 | 0.1% | 2.5% | ||
| Q3 24 | 0.2% | 5.5% | ||
| Q2 24 | 0.0% | 6.6% | ||
| Q1 24 | 0.2% | 1.3% |
| Q4 25 | 0.85× | — | ||
| Q3 25 | 0.61× | 8.15× | ||
| Q2 25 | 1.37× | — | ||
| Q1 25 | 1.06× | 1.43× | ||
| Q4 24 | 1.27× | — | ||
| Q3 24 | 1.66× | 1.98× | ||
| Q2 24 | 1.57× | 2.27× | ||
| Q1 24 | 1.37× | 1.04× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CPRX
| Firdapse | $97.6M | 64% |
| Agamree | $35.3M | 23% |
| Fycompa | $19.6M | 13% |
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |
